Biblio

Found 399 results

Author Keyword Title Type [ Year

]

2009

H. C. Kitchener, Swart, A. Marie, Qian, Q., Amos, C., and Parmar, M. K. B., “Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.”, Lancet, vol. 373, no. 9658, pp. 125-36, 2009.

H. C. Kitchener and Trimble, E. L., “Endometrial cancer state of the science meeting.”, Int J Gynecol Cancer, vol. 19, no. 1, pp. 134-40, 2009.

M. A. Bookman, Brady, M. F., McGuire, W. P., Harper, P. G., Alberts, D. S., Friedlander, M. Leonard, Colombo, N., Fowler, J. M., Argenta, P. A., De Geest, K., Mutch, D. G., Burger, R. A., Swart, A. Marie, Trimble, E. L., Accario-Winslow, C., and Roth, L. M., “Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.”, J Clin Oncol, vol. 27, no. 9, pp. 1419-25, 2009.

I. Ray-Coquard, Weber, B., Cretin, J., Haddad-Guichard, Z., Levy, E., Hardy-Bessard, A. C., Gouttebel, M. C., Geay, J. - F., Aleba, A., Orfeuvre, H., Agostini, C., Provencal, J., Ferrero, J. M., Fric, D., Dohollou, N., Paraiso, D., Salvat, J., Pujade-Lauraine, E., and Group, G. I. N. E. C. O., “Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group”, Br J Cancer, vol. 100, pp. 601-7, 2009.

E. Petru, Luck, H. J., Stuart, G. C. E., Gaffney, D. K., Millan, D., Vergote, I. B., and InterGroup, G. Cancer, “Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system”, Eur J Obstet Gynecol Reprod Biol, vol. 143, pp. 69-74, 2009.

A. M. Poveda and Vermorken, J. B., “The International Symposium on Advanced Ovarian Cancer. February 27, 2009, Spain.”, Int J Gynecol Cancer, vol. 19 Suppl 2, p. S1, 2009.

M. Signorelli, Lissoni, A., Cormio, G., Katsaros, D., Pellegrino, A., Selvaggi, L., Ghezzi, F., Scambia, G., Zola, P., Grassi, R., Milani, R., Giannice, R., Caspani, G., Mangioni, C., Floriani, I., Rulli, E., and Fossati, R., “Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study”, Ann Surg Oncol, vol. 16, pp. 3431-41, 2009.

D. K. Gaffney, du Bois, A., Narayan, K., Reed, N. Simon, Toita, T., Pignata, S., Blake, P., Portelance, L., Sadoyze, A., Potter, R., Colombo, A., Randall, M., Mirza, M. R., and Trimble, E. L., “Patterns of care for radiotherapy in vulvar cancer: a Gynecologic Cancer Intergroup study”, Int J Gynecol Cancer, vol. 19, pp. 163-7, 2009.

C. Pisano, Morabito, A., Sorio, R., Breda, E., Lauria, R., Gebbia, V., Scaltriti, L., Scalone, S., Zagonel, V., Greggi, S., Beneduce, G., Losito, S., Gallo, C., Di Maio, M., Forestieri, V., and Pignata, S., “A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial”, Cancer Chemother Pharmacol, vol. 64, pp. 1021-7, 2009.

Y. Watanabe, Kitagawa, R., Aoki, D., Takeuchi, S., Sagae, S., Sakuragi, N., Yaegashi, N., and Group, D. Committee, “Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group”, Gynecol Oncol, vol. 115, pp. 456-9, 2009.

W. Small, du Bois, A., Bhatnagar, S., Reed, N. Simon, Pignata, S., Potter, R., Randall, M., Mirza, M., Trimble, E. L., Gaffney, D. K., and InterGroup, G. Cancer, “Practice patterns of radiotherapy in endometrial cancer among member groups of the Gynecologic Cancer Intergroup”, Int J Gynecol Cancer, vol. 19, pp. 395-9, 2009.

I. B. Vergote, Calvert, A. H., Kania, M., Kaiser, C., Zimmermann, A. Hayden, and Sehouli, J., “A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer”, Eur J Cancer, vol. 45, pp. 1415-23, 2009.

E. Pujade-Lauraine, Mahner, S., Kaern, J., Gebski, V., Heywood, M., Vasey, P. A., Reinthaller, A., Vergote, I. B., Pignata, S., and Ferrero, A., “A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer: CALYPSO study of the Gynecologic Cancer Intergroup.”, J Clin Oncol , vol. 27, no. 18, 2009.

T. Sugiyama, Kumagai, S., and Hatayama, S., “[Treatments of epithelial ovarian cancer by histologic subtype]”, Gan To Kagaku Ryoho, vol. 36, pp. 187-92, 2009.

2008

E. Eisenhauer, “Addressing unanswered questions in ovarian cancer trial methodology: follow-up of the 2004 Baden-Baden Gynecologic Cancer Intergroup meeting.”, Int J Gynecol Cancer, vol. 18 Suppl 1, pp. 74-5, 2008.

W. Small, Mell, L. K., Anderson, P., Creutzberg, C., Santos, J. De Los, Gaffney, D. K., Jhingran, A., Portelance, L., Schefter, T., Iyer, R., Varia, M., Winter, K., and Mundt, A. J., “Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer.”, Int J Radiat Oncol Biol Phys, vol. 71, no. 2, pp. 428-34, 2008.

S. V. Barrett, Paul, J., Hay, A., Vasey, P. A., Kaye, S. B., Glasspool, R. M., and Group, S. Gynaecolog, “Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial”, Ann Oncol, vol. 19, pp. 898-902, 2008.

G. C. E. Stuart, “Future opportunities of the Gynecological Cancer Intergroup”, Int J Gynecol Cancer, vol. 18 Suppl 1, pp. 71-3, 2008.

G. C. E. Stuart, “Future opportunities of the Gynecological Cancer Intergroup.”, Int J Gynecol Cancer, vol. 18 Suppl 1, pp. 71-3, 2008.

E. Åvall-Lundqvist, Wimberger, P., Gladieff, L., Gebski, V., Huober, J., Floquet, A., Fitzharris, B., Zeimet, A. G., Heywood, M., and Schmalfeldt, B., “Pegylated liposomal doxorubicin-carboplatin vs paclitaxel-carboplatin in relapsing sensitive ovarian cancer: a 500-patient interim safety analysis of the CALYPSO GCIG intergroup phase III study. ”, Proc.Am.Soc.Clin.Oncol. , vol. 26, no. 15S Part I, 2008.

P. A. Vasey, Gore, M. E., Wilson, R. H., Rustin, G. J. S., Gabra, H., Guastalla, J. P., Lauraine, E. P., Paul, J., Carty, K., Kaye, S. B., and Group, S. Gynaecolog, “A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers”, Br J Cancer, vol. 98, pp. 1774-80, 2008.

T. J. Herzog, Powell, M. A., Rader, J. S., Gibb, R. K., Lippmann, L., Coleman, R. L., and Mutch, D. G., “Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.”, Gynecol Oncol, vol. 111, no. 3, pp. 467-73, 2008.

S. Pignata, Breda, E., Scambia, G., Pisano, C., Zagonel, V., Lorusso, D., Greggi, S., De Vivo, R., Ferrandina, G., Gallo, C., and Perrone, F., “A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study”, Crit Rev Oncol Hematol, vol. 66, pp. 229-36, 2008.

N. Simon Reed, Mangioni, C., Malmström, H., Scarfone, G., Poveda, A. M., Pecorelli, S., Tateo, S., Franchi, M., Jobsen, J. J., Coens, C., Teodorovic, I., Vergote, I. B., and Vermorken, J. B., “Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).”, Eur J Cancer, vol. 44, no. 6, pp. 808-18, 2008.

P. Hoskins, Vergote, I. B., Stuart, G. C. E., Cervantes, A., Tu, D., Carey, M. S., Provencher, D. M., Katsaros, D., P, G., and Eisenhauer, E., “A phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (OV.16). A GCIG Study.”, Proc.Am.Soc.Clin.Oncol. , vol. 26, no. 15S Part I, 2008.

Pages